Business Update Neutral

2026-11-05 17:34

- Audio recording of the Analysts/Investors Conference Call held on November 5, 2026, for Q2 and H1 FY27 financial results has been made available. - The audio recording can be accessed on the company's official website.

Business Update Positive

2026-11-04 18:46

- Q2 FY27 revenue grew 30% YoY to ₹316.08 Cr; EBITDA rose 40% YoY to ₹67.65 Cr (21% margin). - PAT surged 57% YoY to ₹39.57 Cr. - Management raised FY27 outlook, expecting revenue growth and EBITDA margins to surpass earlier guidance. - ₹280 Cr capex plan on track for FY27 completion.

Business Update Positive

2026-11-04 18:35

SMS Pharmaceuticals Limited released its Investor Presentation for Q2 and H1 FY27. - Q2FY27 Revenue from operations grew 30% YoY to ₹316 crore, driven by volume growth and improved price realization. - EBITDA rose 40% YoY to ₹68 crore with margins expanding 145 bps to 21%. - Net Profit (PAT) increased 57% YoY to ₹40 crore. - FY27 revenue growth and EBITDA margins are expected to exceed earlier guidance. - Peptides R&D facility is fully operational with pilot scale production targeted for Q4FY27.

Financials Neutral

2026-11-04 13:40

CRITICAL RED FLAG DETECTED

Q2 FY27 Standalone Revenue ₹316.07Cr vs ₹242.43Cr (▲30% YoY) EBITDA ₹67.25Cr vs ₹48.38Cr (▲39% YoY) PAT ₹39.13Cr vs ₹25.14Cr (▲56% YoY) EBITDA Margin 21% vs 20% (▲132bps)

Governance Negative

2026-11-04 13:36

CRITICAL RED FLAG DETECTED

- Mr. Thirumalesh Tumma resigned as Company Secretary, Compliance Officer, and KMP effective November 4, 2026, citing personal reasons. - Mr. Manohar Mollama appointed as new Company Secretary, Compliance Officer, and KMP effective November 5, 2026. - Board also approved Q2 FY27 unaudited financial results.

Financials Neutral

2026-11-04 13:28

CRITICAL RED FLAG DETECTED

Q2 FY27 Consolidated Revenue ₹316.09Cr vs ₹242.43Cr (▲30% YoY) EBITDA ₹67.66Cr vs ₹48.36Cr (▲40% YoY) PAT ₹39.85Cr vs ₹25.31Cr (▲57% YoY) EBITDA Margin 21.4% vs 20.0% (▲145bps) - Resignation of Mr. Thirumalesh Tumma as Company Secretary & Compliance Officer (KMP) effective November 4, 2026. - Appointment of Mr. Manohar Mollama as Company Secretary & Compliance Officer (KMP) effective November 5, 2026.

Business Update Neutral

2026-11-02 15:13

Concall Schedule Concall Date: November 05, 2026 Concall Time: 12:00 noon IST

Routine Neutral

2026-10-31 17:43

- SMS Pharmaceuticals received an appellate order from the Commissioner of Income Tax (Appeals) dated 30th October 2026, dismissing the company's appeal for Assessment Year 2018-19. - The underlying tax demand was earlier reduced from ₹7.19 crores to ₹40.28 lakhs via a rectification order. - The company stated there is no material impact on operations.

Governance Positive

2026-10-31 17:39

- SMS Pharmaceuticals Limited received an appellate order dated October 30, 2026, from the Commissioner of Income Tax (Appeals), allowing the company's appeal for Assessment Year 2023-24. - The outstanding tax demand of Rs. 45.63 Crores, including interest and penalty, stands completely vacated.

Business Update Neutral

2026-10-30 17:20

- SMS Pharmaceuticals Limited has entered into a loan agreement with its subsidiary, SMS Peptides Private Limited. - The company will provide an unsecured loan of up to ₹50 Crores in one or more tranches for business purposes. - SMS Pharmaceuticals holds a 99.99% stake in SMS Peptides Private Limited. - The transaction is conducted on an arm's length basis.

Routine Neutral

2026-09-24 14:25

- Trading window for dealing in company shares closed from October 1, 2026. - Closure applies to all designated persons and their immediate relatives. - Window will reopen 48 hours after declaring Q2/H1 FY27 financial results. - Board meeting date to consider results will be intimated later.

Business Update Neutral

2026-09-10 15:16

- Investor/Analyst Meeting Schedule - Meeting Date: 15 September 2026 - Interaction with: Emkay Global Investors Meeting

Routine Positive

2026-09-04 12:05

- SMS Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, pursuant to SEBI (LODR) Regulations, 2015. - The report details the company's ESG initiatives, governance framework, and performance on sustainability metrics. - It covers strategies for managing risks and opportunities related to supply chain, occupational health, climate action, and resource management.

Business Update Neutral

2026-09-02 08:55

- CARE Ratings Limited reaffirmed Long Term Bank Facilities rating at 'CARE A', with outlook revised from 'Positive' to 'Stable'. - Short Term Bank Facilities rating 'CARE A1' was reaffirmed. - Total Long Term Facilities rated: ₹570.07 Cr (enhanced from ₹350.87 Cr). Total Short Term Facilities: ₹52.83 Cr.

Governance Neutral

2026-08-27 11:39

- The 38th Annual General Meeting (AGM) for the financial year ended March 31, 2026, originally scheduled for Wednesday, September 23, 2026, will now be held on Tuesday, September 29, 2026. - The Record Date for determining dividend eligibility has been revised from Wednesday, September 16, 2026, to Tuesday, September 22, 2026. - The Book Closure period will be from Wednesday, September 23, 2026, to Tuesday, September 29, 2026.

Financials Neutral

2026-08-06 12:58

- SMS Pharmaceuticals Limited issued intimation on Tax Deduction at Source (TDS) on the recommended final dividend of ₹0.40 per equity share for FY 2025-26. - The dividend is subject to approval at the 38th AGM on September 23, 2026, with the Record Date set as September 16, 2026. - Shareholders are required to submit relevant tax documents by September 09, 2026, for appropriate TDS calculation.

Financials Positive

2026-08-01 17:07

- Consolidated Revenue ₹207.0 Cr vs ₹196.1 Cr (▲6% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4% YoY) - PAT ₹20.20 Cr vs ₹18.72 Cr (▲8% YoY) - EBITDA Margin 20% vs 20% (Stable YoY)

Financials Positive

2026-07-31 18:06

- Consolidated Revenue ₹20,696.49 Lakhs vs ₹19,604.71 Lakhs (▲5.57% YoY) - EBITDA ₹4,269.53 Lakhs vs ₹3,996.22 Lakhs (▲6.84% YoY) - PAT ₹2,020.10 Lakhs vs ₹1,871.47 Lakhs (▲7.94% YoY) - EBITDA Margin 20.63% vs 20.38% (▲25bps) - The Board re-appointed Mr. Ramesh Babu Potluri as Chairman & Managing Director for five years effective October 1, 2026. - Approved a loan of up to ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th Annual General Meeting (AGM) for FY2025-26 is scheduled for September 23, 2026.

Financials Positive

2026-07-31 17:40

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.6% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4.0% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.9% YoY) - EBITDA Margin 19.78% vs 20.08% (▼30bps) - Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman & Managing Director for 5 years (Oct 1, 2026 - Sept 30, 2031). - Approved a loan up to ₹50 Cr to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th Annual General Meeting (AGM) is scheduled for September 23, 2026, with September 16, 2026, fixed as the Record Date for dividend eligibility.

Financials Positive

2026-07-31 17:36

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.56% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4.01% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.96% YoY) - EBITDA Margin 19.79% vs 20.08% (▼29bps) - The 38th Annual General Meeting (AGM) for FY 2025-26 is scheduled for September 23, 2026. - Mr. Ramesh Babu Potluri re-appointed as Chairman and Managing Director for 5 years effective October 01, 2026. - Approved a loan up to ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval.

Financials Positive

2026-07-31 17:28

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.57% YoY) - EBITDA ₹42.70 Cr vs ₹39.96 Cr (▲6.84% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.94% YoY) - EBITDA Margin 20.46% vs 20.32% (▲14bps)

Financials Positive

2026-07-31 17:14

- Consolidated Revenue ₹20,696.49 Lakhs vs ₹19,604.71 Lakhs (▲5.6% YoY) - EBITDA ₹4,095.09 Lakhs vs ₹3,936.91 Lakhs (▲4.0% YoY) - PAT ₹2,020.10 Lakhs vs ₹1,871.47 Lakhs (▲7.9% YoY) - EBITDA Margin 19.78% vs 20.08% (▼30bps) - Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026, subject to shareholder approval. - Approved a loan not exceeding ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th AGM is scheduled for September 23, 2026, with September 16, 2026, as the record date for dividend eligibility for FY 2025-26.

SMSPHARMA

SMS Pharmaceuticals Limited

Price Chart

Filing History

Unlock Full History